CRISPR: Disruptive Technologies and Emerging Markets
Tuesday, 18 August 2015, 3.30pm to 8.30pm
Said Business School
Since the discovery that our genes hold the keys to our health, the race has been on to find a precise method to edit our genomes. CRISPR claims to provide the tools to precisely edit genomes with unparalleled simplicity and flexibility, resulting in the potential for a revolutionary step towards curing hereditary disorders and correcting mutations that cause cancer. This breakthrough gene editing technology is barely three years old, however it has already attracted hundreds of millions of dollars from investors, inspiring a multitude of exciting biotech start-ups.
Join us for what is certain to be an informative and inspiring discussion about how entrepreneurs, academics and industry professionals can join in with the battle to exploit the biggest biotech discovery of the decade.
Attendance is free to all Oxford Biotech members, and tickets are guaranteed to sell out once they are released.
Dr Lorenz Mayr, Vice President, Global Head, Biological Reagents & Assay Development, AstraZeneca
Eric Rhodes, Senior Vice President, Chief Technology Officer, Horizon Discovery
Prof Tudor Fulga
Associate Professor of Genome Biology, University of Oxford
Dr Philip Webber, Partner, Dehns (Patent and Trademark Attorney)
Edward Perello, Co-Founder, Chief Business Officer, Desktop Genetics
The speakers are expected to finish at 7.30pm, and then there will be networking with drinks and refreshments where attendees will have the opportunity to engage with our high-profile speakers and sponsors in a less formal setting.
Don't miss this opportunity to join more than 500 registered scientists, industry professionals and entrepreneurs for this major event. Attendance is free to all Oxford Biotech members.